Evidence map›Paper›PMID 36104748›Full record

ArticleCancer cell international2022

Construction and validation of a ferroptosis-related long noncoding RNA signature in clear cell renal cell carcinoma.

Zhenpeng Zhu, Cuijian Zhang, Jinqin Qian, Ninghan Feng, Weijie Zhu, Yang Wang, Yanqing Gong, Xuesong Li, Jian Lin, Liqun Zhou

Abstract read
In one paragraph

Article in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhenpeng Zhu *Department of Urology, Peking University First Hospital, Beijing, 100034, China.
Cuijian Zhang *Department of Urology, Peking University First Hospital, Beijing, 100034, China.
Jinqin QianDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Ninghan FengThe Affiliated Wuxi Second People's Hospital of Nanjing Medical University, Wuxi, 214000, China.
Weijie ZhuDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Yang WangThe Affiliated Wuxi Second People's Hospital of Nanjing Medical University, Wuxi, 214000, China.
Yanqing GongDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Xuesong LiDepartment of Urology, Peking University First Hospital, Beijing, 100034, China. pineneedle@sina.com.
Jian LinDepartment of Urology, Peking University First Hospital, Beijing, 100034, China. linjianbj@163.com.ORCID http://orcid.org/0000-0003-3476-5792
Liqun ZhouDepartment of Urology, Peking University First Hospital, Beijing, 100034, China. zhoulqmail@163.com.

Funding

National Natural Science Foundation of China 81602253National Natural Science Foundation of China 81670617National Natural Science Foundation of China 81672546National Natural Science Foundation of China 81772703National Natural Science Foundation of China 81872083Natural Science Foundation of Beijing 7152146Natural Science Foundation of Beijing 7172219
6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is characterized by the accumulation of lipid-reactive oxygen species. Ferroptosis, due to the lipid peroxidation, has been reported to be strongly correlated with tumorigenesis and progression. However, the functions of the ferroptosis process in ccRCC remain unclear.

methodsAfter sample cleaning, data integration, and batch effect removal, we used the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases to screen out the expression and prognostic value of ferroptosis-related lncRNAs and then performed the molecular subtyping using the K-means method. Then, the functional pathway enrichment and immune microenvironment infiltration between the different clusters were carried out. The results showed a significant difference in immune cell infiltration between the two clusters and the associated marker responded to individualized differences in treatment. Then, least absolute shrinkage and selection operator (LASSO) Cox regression was used to establish a prognostic signature based on 5 lncRNAs. This signature could accurately predicted patient prognosis and served as an independent clinical risk factor. We then combined significant clinical parameters in multivariate Cox regression and the prognostic signature to construct a clinical predictive nomogram, which provides appropriate guidance for predicting the overall survival of ccRCC patients.

resultsThe prognostic differentially expressed ferroptosis-related LncRNAs (DEFRlncRNAs) were found, and 5 lncRNAs were finally used to establish the prognostic signature in the TCGA cohort, with subsequently validation in the internal and external cohorts. Moreover, we conducted the molecular subtyping and divided the patients in the TCGA cohort into two clusters showing differences in Hallmark pathways, immune infiltration, immune target expression, and drug therapies. Differences between clusters contributed to individualizing treatment. Furthermore, a nomogram was established to better predict the clinical outcomes of the ccRCC patients.

conclusionsOur study conducted molecular subtyping and established a novel predictive signature based on the ferroptosis-related lncRNAs, which contributed to the prognostic prediction and individualizing treatment of ccRCC patients.

Indexed as

Clear cell renal cell carcinomaFerroptosisLong Noncoding RNAMolecular subtypingPrognostic signature

Identifiers

PMID36104748
PMCPMC9476564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.